Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shorter and Safer Treatment Regimens for Latent TB
PACTR202607730026709Phase 2Not yet recruiting
- Sponsor
- Research Institute of the McGill University Health Centre
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rifampicin, rifapentine and linezolid in latent tuberculosis infection (LTBI) (3 arms), sponsored by Research Institute of the McGill University Health Centre. Primary endpoints: Safety of the treatment regimen, Treatment tolerability and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
rifampicinrifapentinelinezolid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on PACTR202607730026709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607730026709.